President and CEO Bob Proulx today addressed investors at the Switzer Small and Microcap Investor Day in Sydney Australia. He discussed recent milestones, including FDA breakthrough Device Designation, and what Imagion Biosystems expects to achieve in 2020.
Imagion Initiates Manufacturing of MagSense® Drug for Phase 2 Clinical Study on HER2+ Breast Cancer
February 19, 2025
MELBOURNE – Imagion Biosystems (Company) (ASX : IBX), a company dedicated to improving healthcare outcomes through the early detection of cancer, is pleased to announce